This trade activity should not be overlooked: Navidea Biopharmaceuticals Inc. (NAVB)

Navidea Biopharmaceuticals Inc. (AMEX: NAVB) stock jumped 8.33% on Wednesday to $0.13 against a previous-day closing price of $0.12. With 43.8 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.4 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1465 whereas the lowest price it dropped to was $0.1001. The 52-week range on NAVB shows that it touched its highest point at $1.05 and its lowest point at $0.10 during that stretch. Beta for the stock currently stands at 1.58.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NAVB was up-trending over the past week, with a rise of 14.04%, but this was down by -48.00% over a month. Three-month performance dropped to -55.25% while six-month performance fell -44.99%. The stock lost -83.95% in the past year, while it has lost -38.10% so far this year.

Float and Shares Shorts:

At present, 32.65 million NAVB shares are outstanding with a float of 22.27 million shares on hand for trading. On May 14, 2023, short shares totaled 44280.0, which was 0.13% higher than short shares on Apr 13, 2023. In addition to Mr. Joseph W. Meyer as the firm’s Director of Fin. and Accounting, Controller, Principal Financial & Accounting Officer, Dr. Michael Sherman Blue F.A.C.E.P., M.D. serves as its Chief Medical Officer.

Institutional Ownership:

Through their ownership of 4.98% of NAVB’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 26.50% of NAVB, in contrast to 2.78% held by mutual funds. Shares owned by individuals account for 1.50%. As the largest shareholder in NAVB with 0.84% of the stake, The Vanguard Group, Inc. holds 276,491 shares worth 276,491. A second-largest stockholder of NAVB, Renaissance Technologies LLC, holds 238,133 shares, controlling over 0.73% of the firm’s shares. Allred Capital Management LLC is the third largest shareholder in NAVB, holding 164,738 shares or 0.50% stake. With a 0.84% stake in NAVB, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 276,491 shares are owned by the mutual fund manager. The Bridgeway Ultra Small Company Mar, which owns about 0.31% of NAVB stock, is the second-largest Mutual Fund holder. It holds 102,440 shares valued at 26839.0. Fidelity Extended Market Index Fu holds 0.21% of the stake in NAVB, owning 69,656 shares worth 18250.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, NAVB reported revenue of $6.52k and operating income of -$2.92M. The EBITDA in the recently reported quarter was -$2.90M and diluted EPS was -$0.10.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NAVB since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With NAVB analysts setting a high price target of $8.00 and a low target of $8.00, the average target price over the next 12 months is $8.00. Based on these targets, NAVB could surge 6053.85% to reach the target high and rise by 6053.85% to reach the target low. Reaching the average price target will result in a growth of 6053.85% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded NAVB stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 24 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 119,900 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *